Sénescence cellulaire et thérapies anti-sénescence dans la cirrhose biliaire pédiatrique – JR 2025

Value of the Information & Strength of the Argument

The presentation provides valuable insights into a poorly understood mechanism in pediatric biliary disease. The argumentation is solid, based on a multi-technique approach to confirm senescence, including histology, gene expression, and spatial transcriptomics. The speaker acknowledges limitations, such as small sample sizes and the descriptive nature of the human studies. The preclinical model is well-designed, and the negative results with dasatinib/quercetin are important for the field. The discussion of the lack of specificity of current senolytics is critical and well-argued.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high: the study uses established markers and techniques, and the speaker cites relevant literature (e.g., gene lists from published studies). The sources are not explicitly cited in the video, but the description provides links to the organization’s website and social media, which are not direct references. The title accurately reflects the content. The presentation is part of a professional conference, indicating peer context.

The title accurately reflects the content, which focuses on cellular senescence and anti-senescence therapies in pediatric biliary cirrhosis.

8/10

The presentation is based on original research with a clear methodology, including multiple markers and techniques to assess senescence, and discusses limitations. The speaker is a medical doctor presenting at a specialized conference. However, the study is descriptive and based on small sample sizes, and the preclinical results are preliminary.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction to cellular senescence: replicative and premature senescence, markers, and SASP.
• 02:00Senescence in adult liver diseases and rationale for studying pediatric biliary atresia.
• 05:00Study design: 30 biliary atresia livers at Kasai, 5 at transplant, 5 controls; detection of SA-β-gal and p16.
• 08:00Immunofluorescence for γH2AX, CK19, HNF4α; senescence predominates in cholangiocytes and progresses.
• 10:00SASP gene expression (IL6, IL8, TGFβ1) increased in advanced stages.
• 12:00Spatial transcriptomics confirms senescence gene signatures in cholangiocytes.
• 15:00Preclinical model: bile duct ligation in rats; senescence develops in cholangiocytes first.
• 18:00Testing HALPC cells and dasatinib+quercetin; short-term effects of HALPC, no effect of senolytics.
• 20:00Long-term experiment shows no benefit; discussion of specificity issues.
• 22:00Senescence in Alagille syndrome livers; advanced senescence despite Notch mutations; conclusions.

• FILFOIE website — Organization website providing information about the rare liver disease network.

• FILFOIE website — The organization hosting the conference, providing context for the research.